ERYP Stock Overview
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States.
+ 1 more risk
ERYTECH Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.57|
|52 Week High||€5.50|
|52 Week Low||€0.54|
|1 Month Change||-33.62%|
|3 Month Change||-48.79%|
|1 Year Change||-88.82%|
|3 Year Change||-85.44%|
|5 Year Change||-97.66%|
|Change since IPO||-95.02%|
Recent News & Updates
|ERYP||FR Biotechs||FR Market|
Return vs Industry: ERYP underperformed the French Biotechs industry which returned -55.4% over the past year.
Return vs Market: ERYP underperformed the French Market which returned -12.7% over the past year.
|ERYP Average Weekly Movement||8.7%|
|Biotechs Industry Average Movement||7.3%|
|Market Average Movement||4.9%|
|10% most volatile stocks in FR Market||9.3%|
|10% least volatile stocks in FR Market||2.8%|
Stable Share Price: ERYP is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ERYP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers.
ERYTECH Pharma Fundamentals Summary
|ERYP fundamental statistics|
Is ERYP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ERYP income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 08, 2022
|Earnings per share (EPS)||-0.87|
|Net Profit Margin||-938.49%|
How did ERYP perform over the long term?See historical performance and comparison
Is ERYP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ERYP?
Other financial metrics that can be useful for relative valuation.
|What is ERYP's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ERYP's PS Ratio compare to its peers?
|ERYP PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ERYP ERYTECH Pharma
Price-To-Sales vs Peers: ERYP is expensive based on its Price-To-Sales Ratio (6.2x) compared to the peer average (4.4x).
Price to Earnings Ratio vs Industry
How does ERYP's PE Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Sales vs Industry: ERYP is expensive based on its Price-To-Sales Ratio (6.2x) compared to the French Biotechs industry average (6.1x)
Price to Sales Ratio vs Fair Ratio
What is ERYP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.2x|
|Fair PS Ratio||31.3x|
Price-To-Sales vs Fair Ratio: ERYP is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (31.3x).
Share Price vs Fair Value
What is the Fair Price of ERYP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ERYP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ERYP's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is ERYTECH Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERYP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ERYP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ERYP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ERYP's revenue (77.2% per year) is forecast to grow faster than the French market (5.3% per year).
High Growth Revenue: ERYP's revenue (77.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ERYP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has ERYTECH Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ERYP is currently unprofitable.
Growing Profit Margin: ERYP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ERYP is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare ERYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ERYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Return on Equity
High ROE: ERYP has a negative Return on Equity (-119.76%), as it is currently unprofitable.
Discover strong past performing companies
How is ERYTECH Pharma's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ERYP's short term assets (€62.1M) exceed its short term liabilities (€27.6M).
Long Term Liabilities: ERYP's short term assets (€62.1M) exceed its long term liabilities (€16.0M).
Debt to Equity History and Analysis
Debt Level: ERYP has more cash than its total debt.
Reducing Debt: ERYP's debt to equity ratio has increased from 3.5% to 82.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ERYP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ERYP has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 16.1% each year.
Discover healthy companies
What is ERYTECH Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|ERYTECH Pharma Dividend Yield vs Market|
|Company (ERYTECH Pharma)||n/a|
|Market Bottom 25% (FR)||2.0%|
|Market Top 25% (FR)||6.2%|
|Industry Average (Biotechs)||2.2%|
|Analyst forecast in 3 Years (ERYTECH Pharma)||n/a|
Notable Dividend: Unable to evaluate ERYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ERYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ERYP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ERYP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ERYP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gil Beyen (60 yo)
Mr. Gil Beyen, BVBA has been the Chief Executive Officer of ERYTECH Pharma S.A. since May 2013. For more than ten years, Mr. Beyen has been a Management Consultant at Arthur D. Little in Brussels and serve...
CEO Compensation Analysis
|Gil Beyen's Compensation vs ERYTECH Pharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||€751k||€399k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||€957k||€409k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||€791k||€399k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||€657k||€345k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||€645k||€276k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||€611k||€276k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||€414k||€270k|
Compensation vs Market: Gil's total compensation ($USD733.72K) is above average for companies of similar size in the French market ($USD342.35K).
Compensation vs Earnings: Gil's compensation has been consistent with company performance over the past year.
Experienced Management: ERYP's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: ERYP's board of directors are seasoned and experienced ( 10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.9%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
ERYTECH Pharma S.A.'s employee growth, exchange listings and data sources
- Name: ERYTECH Pharma S.A.
- Ticker: ERYP
- Exchange: ENXTPA
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €17.726m
- Shares outstanding: 31.02m
- Website: https://www.erytech.com
Number of Employees
- ERYTECH Pharma S.A.
- 60 Avenue Rockefeller
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ERYP||ENXTPA (Euronext Paris)||Yes||Category O Shares||FR||EUR||Apr 2013|
|ERYPP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Category O Shares||GB||EUR||Apr 2013|
|0QSS||LSE (London Stock Exchange)||Yes||Category O Shares||GB||EUR||Apr 2013|
|20000||DB (Deutsche Boerse AG)||Yes||Category O Shares||DE||EUR||Apr 2013|
|ERYP||NasdaqGS (Nasdaq Global Select)||SPON ADR EACH REPR 1 ORD||US||USD||Mar 2015|
|2E4A||DB (Deutsche Boerse AG)||SPON ADR EACH REPR 1 ORD||DE||EUR||Mar 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.